| Molecular Formula | C128H205N45O39S2 |
| Molar Mass | 3062.41 |
| Solubility | 0.05 M acetic acid: 1mg/mL, clear, colorless |
| Storage Condition | -20°C |
| Use | Atrial Natriuretic Peptide (ANP) (1-28), rat is a major circulating form of ANP in rats, potently in |
| In vitro study | Rat ANP (1-28) and rat BNP-45, which are the respective major circulating forms of ANP and BNP in rats, potently inhibited Ang II-stimulated endothelin-1 secretion in a concentration-dependent manner. Rat ANP (5-25) is less effective that Rat ANP(1-28) with respect to inhibiting immunoreactive (ir)-endothelin-1 secretion and increasing cellular cyclic GMP. Rat ANP (1-28) inhibits the secretion of ir-endothelin-1 in a concentration-dependent manner between 0.01 and 1 μM. |
| Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
| WGK Germany | 3 |
| FLUKA BRAND F CODES | 10 |
| biological activity | Atrial Natriuretic Peptide (ANP) (1-28), rat is the main circulating form of atrial natriuretic peptide (ANP) in rats, which strongly inhibits angiotensin II (Ang II)-stimulated endothelin-1 (endothelin-1) secretion. |
| target | Endothelin-1 |
| in vitro research | Rat ANP (1-28) and rat BNP-45, which are the respective major circulating forms of ANP and BNP in rats, potently inhibited Ang II-stimulated endothelin-1 secretion in a concentration-dependent manner. Rat ANP (5-25) is less effective that Rat ANP (1-28) with respect to inhibiting immunoreactive (ir)-endothelin-1 secretion and increasing cellular cyclic GMP. Rat ANP (1-28) inhibits the secretion of ir-endothelin-1 in a concentration-dependent manner between 0.01 and 1 μM. |